IMBRS22048_Dhakal_Celcuity CELC-G-301 Gedatolisib
Basic Study Information
Purpose:
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy
and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment
of patients with locally advanced or metastatic HR+/HER2- breast cancer following
progression on or after CDK4/6 and aromatase inhibitor therapy.
Location: University of Rochester Medical Center
Lead Researcher (Principal Investigator)
Lead Researcher:
Ajay Dhakal
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search